Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$6.65B
sum of reported positions
Reported positions
108
Changes vs prior quarter
96
29 new · 14 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 138 measured positions in 8 quarters, the typical new or larger position finished −0.1 pts against the S&P 500 and 50% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
| 2.04M | $682M | 10.3% | |
| 4.32M | $383M | 5.8% | |
| 3.2M | $334M | 5.0% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $5.1B | $6.65B |
| Positions | 93 | 108 |
| Biggest line | — | Praxis Precision Medicines 10% |
| 1.16M |
| $310M |
| 4.7% |
| 2.59M | $287M | 4.3% |
| 8.09M | $286M | 4.3% |
| 14.1M | $264M | 4.0% |
| 3.75M | $213M | 3.2% |
| 8.2M | $196M | 2.9% |
NUVALENT INC | 1.58M | $195M | 2.9% |
| 4.37M | $178M | 2.7% |
APOGEE THERAPEUTICS INC | 1.31M | $174M | 2.6% |
| 8.33M | $150M | 2.3% |
| 10.8M | $146M | 2.2% |
| 1.35M | $128M | 1.9% |
| 1.3M | $123M | 1.8% |
| 982K | $120M | 1.8% |
| 11.9M | $119M | 1.8% |
| 4.18M | $109M | 1.6% |
| 3.38M | $106M | 1.6% |
| 10.4M | $105M | 1.6% |
| 4.32M | $105M | 1.6% |
| 10.3M | $103M | 1.6% |
| 528K | $98.8M | 1.5% |
| 2.68M | $88.1M | 1.3% |
Ionis Pharmaceuticals (IONS)
504K → 566K shares (+12%)
Sutro Biopharma (STRO)
715K → 1.3M shares (+82%)
Alto Neuroscience (ANRO)
2.01M → 1.61M shares (−20%)
Corvus Pharmaceuticals (CRVS)
2.29M → 2.67M shares (+16%)
Sionna Therapeutics (SION)
658K → 905K shares (+37%)
Cytomx Therapeutics (CTMX)
10.1M → 10.4M shares (+3%)
Artivion (AORT)
1.64M → 1.74M shares (+6%)
X4 Pharmaceuticals (XFOR)
6.74M → 7.93M shares (+18%)
Corcept Therapeutics (CORT)
50K → 398K shares (+697%)
Repligen (RGEN)
281K → 248K shares (−12%)
Rapport Therapeutics (RAPP)
674K → 773K shares (+15%)
Charles River Laboratories (CRL)
140K shares
Axsome Therapeutics (AXSM)
150K → 118K shares (−21%)
Eyepoint (EYPT) · PUT
2M shares
Dbv Technologies (DBVT)
964K → 1.65M shares (+71%)
Irhythm Holdings (IRTC)
105K → 224K shares (+113%)
Adaptive Biotechnologies (ADPT)
153K → 1.22M shares (+698%)
Sab Biotherapeutics (SABS)
6.43M → 6.63M shares (+3%)
Danaher Corporation (DHR)
130K shares
Tenax Therapeutics (TENX)
1.45M → 1.7M shares (+17%)
Capricor Therapeutics (CAPR) · CALL
1M shares
Sellas Life Sciences Group (SLS) · PUT
1.5M shares
Nautilus Biotechnology (NAUT)
12.6M → 11.6M shares (−8%)
Intuitive Surgical (ISRG)
85K → 52K shares (−39%)
Adlai Nortye Group (ANL)
1.79M shares
